» Articles » PMID: 26114124

The Lung Immune Response to Nontypeable Haemophilus Influenzae (Lung Immunity to NTHi)

Overview
Journal J Immunol Res
Publisher Wiley
Date 2015 Jun 27
PMID 26114124
Citations 33
Authors
Affiliations
Soon will be listed here.
Abstract

Haemophilus influenzae is divided into typeable or nontypeable strains based on the presence or absence of a polysaccharide capsule. The typeable strains (such as type b) are an important cause of systemic infection, whilst the nontypeable strains (designated as NTHi) are predominantly respiratory mucosal pathogens. NTHi is present as part of the normal microbiome in the nasopharynx, from where it may spread down to the lower respiratory tract. In this context it is no longer a commensal and becomes an important respiratory pathogen associated with a range of common conditions including bronchitis, bronchiectasis, pneumonia, and particularly chronic obstructive pulmonary disease. NTHi induces a strong inflammatory response in the respiratory tract with activation of immune responses, which often fail to clear the bacteria from the lung. This results in recurrent/persistent infection and chronic inflammation with consequent lung pathology. This review will summarise the current literature about the lung immune response to nontypeable Haemophilus influenzae, a topic that has important implications for patient management.

Citing Articles

Alpha-defensins increase NTHi binding but not engulfment by the macrophages enhancing airway inflammation in Alpha-1 antitrypsin deficiency.

Lee J, Mohammad N, Han K, Flagg-Dowie T, Magallon M, Brantly M Front Immunol. 2025; 16:1543729.

PMID: 40013145 PMC: 11861504. DOI: 10.3389/fimmu.2025.1543729.


NTHi killing activity is reduced in COPD patients and is associated with a differential microbiome.

Gopalakrishnan V, Sparklin B, Kim J, Bouquet J, Kehl M, Kenny T Respir Res. 2025; 26(1):45.

PMID: 39885466 PMC: 11781068. DOI: 10.1186/s12931-025-03113-z.


Tolerance to Haemophilus influenzae infection in human epithelial cells: Insights from a primary cell-based model.

Kappler U, Henningham A, Nasreen M, Yamamoto A, Buultjens A, Stinear T PLoS Pathog. 2024; 20(7):e1012282.

PMID: 38990812 PMC: 11239077. DOI: 10.1371/journal.ppat.1012282.


An Isolate of Displayed In Vitro Antimicrobial Activity and Deleterious Effect in a Preclinical Model of Lung Infection.

Mathieu E, Marquant Q, Chain F, Bouguyon E, Saint-Criq V, Le-Goffic R Nutrients. 2023; 15(2).

PMID: 36678133 PMC: 9867278. DOI: 10.3390/nu15020263.


miR449 Protects Airway Regeneration by Controlling AURKA/HDAC6-Mediated Ciliary Disassembly.

Wildung M, Herr C, Riedel D, Wiedwald C, Moiseenko A, Ramirez F Int J Mol Sci. 2022; 23(14).

PMID: 35887096 PMC: 9320302. DOI: 10.3390/ijms23147749.


References
1.
Murphy T, Brauer A, Sethi S, Kilian M, Cai X, Lesse A . Haemophilus haemolyticus: a human respiratory tract commensal to be distinguished from Haemophilus influenzae. J Infect Dis. 2006; 195(1):81-9. DOI: 10.1086/509824. View

2.
Teo E, House H, Lockhart K, Purchuri S, Pushparajah J, Cripps A . Haemophilus influenzae oral vaccination for preventing acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2014; (9):CD010010. DOI: 10.1002/14651858.CD010010.pub2. View

3.
Berenson C, Garlipp M, Grove L, Maloney J, Sethi S . Impaired phagocytosis of nontypeable Haemophilus influenzae by human alveolar macrophages in chronic obstructive pulmonary disease. J Infect Dis. 2006; 194(10):1375-84. DOI: 10.1086/508428. View

4.
Wahl S . Transforming growth factor beta: the good, the bad, and the ugly. J Exp Med. 1994; 180(5):1587-90. PMC: 2191721. DOI: 10.1084/jem.180.5.1587. View

5.
Jono H, Shuto T, Xu H, Kai H, Lim D, Gum Jr J . Transforming growth factor-beta -Smad signaling pathway cooperates with NF-kappa B to mediate nontypeable Haemophilus influenzae-induced MUC2 mucin transcription. J Biol Chem. 2002; 277(47):45547-57. DOI: 10.1074/jbc.M206883200. View